Myelodysplastic syndrome/acute myelogenous leukaemia related to adjuvant chemotherapy with oral pyrimidine anti-metabolites.
Abe
M
M
Tanaka
Y
Y
Shinohara
M
M
Kosaka
M
M
Matsumoto
T
T
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D004334:Drug Administration Schedule; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy; D005641:Tegafur / Q000009:adverse effects*; D013997:Time Factors; D014498:Uracil / Q000009:adverse effects
D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D005641:Tegafur; D014498:Uracil